Top Markets
#1 Islamic Coin Islamic Coin +151.46%
#2 DOVU DOVU +50.50%
#3 Velvet Velvet +35.70%
#4 Black Phoenix Black Phoenix +34.70%
#5 Akedo Akedo +14.19%
#6 DoubleZero DoubleZero +12.81%
#7 Not in Employment, Education, or Training Not in Employment, Education, or Training +11.80%
#8 HOME HOME +11.06%
#9 Cross Cross +10.56%
#10 Pieverse Pieverse +9.40%
Coin of the day
Islamic Coin Islamic Coin
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Hexima Limited Hexima Limited

Hexima Limited

HXL
Rangering i aksjer #39776
Hexima Limited is a biotechnology firm focused on the discovery and advancement... Hexima Limited is a biotechnology firm focused on the discovery and advancement of plant-derived proteins and peptides for medical applications in humans. Its primary drug candidate, pezadeftide, a plant defensin, is presently undergoing Phase IIb clinical evaluations in Australia and New Zealand to address fungal toenail infections. The company was established in 1997 and its main operations are situated in Preston, Australia.
Aksjekurs
$0.0084929
Sist synkronisert: 2024-11-12
Markedsverdi
$354.66K
Endring (1 dag)
-0.64%
Endring (1 år)
0.00%
Land
AU
Handel Hexima Limited (HXL)

Kategori

Healthcare
Inntekter for Hexima Limited (HXL)
Inntekter i 2026 TTM: 0
Ifølge Hexima Limited sine nyeste økonomiske rapporter er selskapets nåværende resultat 0. I 2026 hadde selskapet et resultat på 0, lik resultatet i 2026, som var 0. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Hexima Limited fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE